The Inhibitory Effect of CD46, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies
Open Access
- 1 April 2002
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 82 (4) , 483-493
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated DamageLaboratory Investigation, 2000
- Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related componentsEuropean Journal of Cancer, 1998
- Human complement regulator expression by the normal female reproductive tractThe Anatomical Record, 1996
- Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL)Clinical and Experimental Immunology, 1995
- Augmented Lung Adenocarcinoma Cytotoxicity by the Combination of a Genetically Modified Anti‐Lewis Y Antibody and Antibodies to Complement Regulatory ProteinsScandinavian Journal of Immunology, 1995
- Human papillomaviruses and cervical neoplasia. I. Classification, virology, pathology, and epidemiology.Journal of Clinical Pathology, 1994
- Cancer statistics, 1994CA: A Cancer Journal for Clinicians, 1994
- Distribution of Complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasmsBritish Journal of Dermatology, 1992
- Induction of tumor‐cell lysis by bi‐specific monoclonal antibodies recognizing renal‐cell carcinoma and cd3 antigenInternational Journal of Cancer, 1989
- Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidneyInternational Journal of Cancer, 1986